Lund, Sweden, November 12, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced new preclinical data highlighting the 4-1BB (CD137) antibody ATOR-1017 including an update on the ongoing phase 1 study. ATOR-1017, a promising candidate for immunotherapy with enormous potential for combination with other immunomodulatory antibodies, will be presented at the Society for Immunotherapy Cancer’s (SITC) 36th Annual Meeting & Pre-Conference Programs virtually on November 10th – 14th, 2021.
"By combining ATOR-1017 with antibodies blocking PD-1, tumor infiltrating T cells, in particular exhausted tumor specific T cells, can be more effectively activated and potentially increase the response rate in multiple types of cancer," stated Karin Enell Smith, PhD, MS, Principal Scientist at Alligator Bioscience. “The functional activation profile of ATOR-1017 is expected to minimize the risk of systemic immune activation and toxicity, by directing a potent immune response to immune cells in tumor tissue and tumor draining lymph nodes. This is supported by early data from the ongoing first-in human phase I study where ATOR-1017 has been shown to be safe and tolerable. These results support further clinical development of ATOR-1017 in combination with PD-1 blocking antibodies”
In addition, the poster includes data from the 360 mg cohort of the ongoing ATOR-1017 phase 1 study.
Title: ATOR-1017, a second generation 4-1BB antibody with potential to
enhance efficacy of PD-1 therapies
Presenter: Karin Enell Smith, PhD, MS
Virtual Meeting: E-Posters Session: Poster
The above poster presentations will be available online at www. www.alligatorbioscience.se on Saturday, November 13, 2021.
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.